0001493152-24-028163.txt : 20240717 0001493152-24-028163.hdr.sgml : 20240717 20240717160710 ACCESSION NUMBER: 0001493152-24-028163 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240717 DATE AS OF CHANGE: 20240717 EFFECTIVENESS DATE: 20240717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-519084 FILM NUMBER: 241122267 BUSINESS ADDRESS: STREET 1: 800 S. GAY STREET STREET 2: SUITE 1610 CITY: KNOXVILLE STATE: TN ZIP: 37929 BUSINESS PHONE: (866) 594-5999 MAIL ADDRESS: STREET 1: 800 S. GAY STREET STREET 2: SUITE 1610 CITY: KNOXVILLE STATE: TN ZIP: 37929 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 D 1 primary_doc.xml X0708 D LIVE 0000315545 PROVECTUS BIOPHARMACEUTICALS, INC. 800 S. GAY STREET SUITE 1610 KNOXVILLE TN TENNESSEE 37929 866-594-5999 DELAWARE None PROVECTUS PHARMACEUTICALS INC ZAMAGE DIGITAL IMAGING INC SPM GROUP INC Corporation true Webster Bailey 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Director John Lacey, III 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Director Edward Pershing 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Director Dominic Rodrigues 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Director Heather Raines 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Executive Officer Eric Wachter 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Executive Officer Pharmaceuticals $1 - $1,000,000 06b false true false true true false 0 10000000 0 10000000 false 0 0 0 0 Proceeds will be used to fund the Company's drug discovery and development program, as currently constituted and envisioned, and to fund the Company's general and administrative expenses. false PROVECTUS BIOPHARMACEUTICALS, INC. /s/ Heather Raines Heather Raines Chief Financial Officer 2024-07-17